GL 522 Y 1

Drug Profile

GL 522 Y 1

Alternative Names: Y 1

Latest Information Update: 03 Jun 1999

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genelabs Technologies
  • Class Antithrombotics; Vascular disorder therapies
  • Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atherosclerosis; Deep vein thrombosis; Embolism; Thrombosis; Unstable angina pectoris

Most Recent Events

  • 03 Jun 1999 A preclinical study has been added to the Thromboses pharmacodynamics section
  • 07 Mar 1996 Discontinued-Preclinical for Atherosclerosis in USA (Unknown route)
  • 07 Mar 1996 Discontinued-Preclinical for Deep vein thrombosis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top